Abbott Forecasts Q1 EPS Growth of 5.5% on $11.03B Revenue
Abbott closed at $114.12, slipping 1.92% while the S&P 500 gained 0.04%, though its shares have risen 6.45% over the past month. Q1 earnings are forecast at $1.15 per share on $11.03 billion revenue, and full-year EPS and sales growth estimates stand at +10.3% and +7.7%.
1. Trading Performance
Abbott shares ended the session at $114.12, down 1.92% while the S&P 500 rose 0.04%. Over the past month, Abbott outpaced its medical sector peers with a 6.45% gain versus a 0.92% sector rise and a 1.33% drop in the broader index.
2. Q1 and Full-Year Estimates
Analysts project Q1 EPS of $1.15, up 5.5% from last year, on revenue of $11.03 billion, reflecting a 6.53% increase. Full-year consensus forecasts call for $5.68 EPS (+10.29%) and $47.74 billion in sales (+7.7%).
3. Valuation Metrics
Abbott trades at a forward P/E of 20.49, slightly below the industry average of 20.63, and holds a PEG ratio of 1.85 versus a sector average of 1.78. These measures suggest modest valuation support given its growth outlook.
4. Analyst Rankings and Revisions
The consensus EPS estimate has ticked down 0.06% over the past month, leaving Abbott with a Zacks Rank of #3 (Hold). This ranking reflects mixed analyst sentiment on near-term momentum and profit potential.